AAD 2026: Toward Precision Medicine in Psoriasis – What It Means for Patients

In this overview, Lars Werner, CEO of the Danish Psoriasis Association, reflects on the key takeaways from AAD 2026 and shares his perspective on how precision medicine, biomarkers, and new systemic treatments are reshaping psoriasis care and changing the understanding of psoriasis as a complex inflammatory disease.